A clinical study on repaglinide therapy of diabetes mellitus after renal transplantation
YAN Fuqin1, XU Chun2, CHEN Haimei2, and NIU Yujian3
1.Department of Pharmacy, 2. Department of Endocrinology, 3. Institute of Organ Transplantation, General Hospital of Chinese People’s Armed Police Force, Beijing 100039, China
Abstract：Objective To study the efficacy and safety of repaglinide therapy in patients with post-transplantation diabetes mellitus(PTDM). Methods To all the patients diagnosed as having PTDM,recrnited in this hospital from January 1,2009 to June 30, 2010 repaglinide was administered for 6 months. Glucose level, hepatic and renal function indicators and FK-506 concentration were examined at baseline, 1 month, 3 months and 6 months of repaglinide therapy. Results 32 patients were included. Except 10 patrents who required insulin glargine therapy due to their poor blood glucose control, the remaining 22 cases received satisfactory glycemic control with repaglinide alone. The levels of FBG, PBG at 1 month, 3 months or 6 months of treatment were significantly lower than those at baseline respectively (P<0.05). The level of Hb1AC at 6 months (6.20%±0.3%) was significantly lower than that at baseline(7.50%±0.63%;P＜0.05). Indicators of hepatic and renal functions and serum FK-506 concentration showed no significant change before and after repaglinide therapy. In the course of treatment hypoglycemia occurred 6 times, in which the lowest blood glucose level was 3.7 mmol/L, no severe hypoglycemia oleveloped. Conclusions Repaglinide can be a safe and effective therapy in patients with PTDM.
闫赋琴，徐 春，程海梅，牛玉坚. 瑞格列奈治疗肾移植后糖尿病的疗效和安全性[J]. 武警医学, 2016, 27(5): 449-451.
YAN Fuqin, XU Chun, CHEN Haimei, and NIU Yujian. A clinical study on repaglinide therapy of diabetes mellitus after renal transplantation. Med. J. Chin. Peop. Armed Poli. Forc., 2016, 27(5): 449-451.
Jelmesaeth J, Jessen T, Hartmann A. Diagnosing of PTDM[J]. Transplantation, 2003, 75(10):1761.
[2]
Eckhard M, Schindler R A, Renner F C, et al. New-onset diabetes mellitus after renal transplantation[J]. Transplant Proc, 2009, 41(6): 2544-2545.
[3]
Gomes M B, Cobas R A. Post-transplant diabetes mellitus[J]. Diabetol Metab Syndr, 2009, 1(1): 14.
[4]
Gnatta D, Keitel E, Heineck I, et al. Use of tacrolimus and the development of posttransplant diabetes mellitus: a Brazilian single-center, observational study[J]. Transplant Proc, 2010, 42(2): 475-478.
[5]
Pérez-Flores I, Sánchez-Fructuoso A, Calvo N, et al. Incidence and risk factors for the metabolic syndrome and posttransplant diabetes in renal transplant recipients taking tacrolimus[J]. Transplant Proc, 2010, 42(8): 2902-2904.
[6]
Davidson J A, Wilkinson A. New-onset diabetes after transplantation 2003 international consensus guidelines[J]. Diabetes Care, 2004,27(3):805-812.
[7]
Turk T, Pietruck F, Dolffa S, et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation[J]. Am J Transplant, 2006, 6(4): 842-846.
Johansen O E, Birkeland K I. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review [J]. Am J Cardiovasc Drugs, 2007,7(5):319-335.
2016, Vol. 27 
